- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06900413
ESP vs. Exora -blokker for smertestillende i laparoskopisk kolecystektomi
Sammenligning av effekten av erektor spinae plan (esp) og ekstern skrå og rectus abdominis plan (exora) blokker i laparoskopisk kolecystektomi
Patients undergoing laparoscopic cholecystectomy may experience moderate to severe postoperative pain. Effective postoperative analgesia enhances patient comfort and accelerates recovery. This study aims to compare the effects of Erector Spinae Plane (ESP) and External Oblique and Rectus Abdominis Plane (EXORA) blocks on postoperative pain management and analgesic consumption.
The study is designed as a prospective, randomized, double-blind trial. Patients will be randomly assigned to groups, and both practitioners and evaluators will be blinded to group assignments. Our hypothesis is that the EXORA block will provide superior analgesia and require less analgesic consumption compared to the ESP block. The results will be assessed in terms of postoperative pain management, patient comfort, and additional analgesic requirements.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Kütahya, Tyrkia (Türkiye)
- Kütahya City Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Age between 18 and 65 years
Undergoing elective laparoscopic cholecystectomy
Classified as American Society of Anesthesiologists (ASA) physical status I to III
Providing written informed consent
Exclusion Criteria:
Known allergy or hypersensitivity to local anesthetics
Infection or skin lesions at the site of block application
Emergency surgical procedures
Refusal to participate in the study
Uncontrolled arterial hypertension
Uncontrolled diabetes mellitus
Mental retardation
Current use of antidepressant medications
Presence of metabolic disorders
Known bleeding diathesis
Morbid obesity (Body Mass Index > 40 kg/m²)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Group ESP
The ESP block will be performed approximately 30 minutes before general anesthesia induction following sedation and standard monitoring. All block procedures will be conducted under sterile conditions, with skin preparation using dermol (%70 Isopropyl Alcohol, %2 Chlorhexidine Gluconate) and the ultrasound probe covered with a sterile drape. |
Experienced anesthesiologists with at least five years of expertise in regional anesthesia will perform the blocks under ultrasound guidance. A 4.0-12.0 MHz linear ultrasound probe (Affiniti 50; Philips) will be used. The ESP block will be applied at the T8 level on the right side, using an in-plane approach, while the patient is in a sitting position. The probe will be placed 2-3 cm lateral to the vertebra in a sagittal position to visualize the erector spinae muscle and transverse processes. A 22G, 100 mm block needle (Stimuplex® Ultra, Braun, Germany) will be advanced in a craniocaudal direction. The correct needle position will be confirmed by injecting 0.5-1 mL of isotonic NaCl and observing the spread via hydrodissection. Finally, 0.3 mL/kg of 0.25% bupivacaine will be administered, ensuring cranial and caudal spread of the local anesthetic. |
|
Aktiv komparator: Group EXORA
The EXORA block will be performed 30 minutes before general anesthesia induction, following sedation and standard monitoring. |
Experienced anesthesiologists with at least five years of expertise in regional anesthesia will administer the blocks under ultrasound guidance. A 4.0-12.0 MHz linear ultrasound probe will be placed laterally to the xiphoid process on the parasternal line in a sagittal position. The probe will be moved craniocaudally to identify the 6th rib and further advanced caudally to locate the 8th rib. Once the rectus abdominis muscle and 8th costal cartilage are identified, a 22G, 100 mm block needle will be used to administer 0.3 mL/kg of 0.25% bupivacaine. The correct spread of the local anesthetic will be confirmed via ultrasound. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Tramadol consumption
Tidsramme: 12 and 24 hours
|
Total tramadol used in the first 12 and 24 hours postoperatively. |
12 and 24 hours
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Visual Analog Scale (VAS) for Pain Assessment
Tidsramme: 30 minutes, 2 hours, 4 hours, 8 hours, 12 hours, and 24 hours after surgery
|
Postoperative pain will be assessed using the Visual Analog Scale (VAS), which ranges from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate a worse outcome (more pain). Units on a scale (0-10) |
30 minutes, 2 hours, 4 hours, 8 hours, 12 hours, and 24 hours after surgery
|
|
Pinprick Sensory Block Test Results
Tidsramme: 10 minutes, 20 minutes, and 30 minutes after the block, and 30 minutes after surgery
|
Sensory block efficacy will be evaluated using the pinprick test at specified time intervals. The presence or absence of sensory block will be recorded. Binary (Block present / Block absent) |
10 minutes, 20 minutes, and 30 minutes after the block, and 30 minutes after surgery
|
|
Nausea and Vomiting Score (NVS)
Tidsramme: Within 24 hours after surgery
|
Postoperative nausea and vomiting will be evaluated using the Nausea and Vomiting Scale (NVS), which includes:
|
Within 24 hours after surgery
|
|
Ramsay Sedation Scale (RSS)
Tidsramme: Within 24 hours after surgery
|
Postoperative sedation will be assessed using the Ramsay Sedation Scale (RSS), which includes:
|
Within 24 hours after surgery
|
|
Additional Analgesic Consumption
Tidsramme: Within 24 hours after surgery
|
The total amount of additional analgesics administered postoperatively will be recorded. Milligrams (mg) |
Within 24 hours after surgery
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Total Antiemetic Consumption
Tidsramme: Within 24 hours after surgery
|
The total amount of antiemetic medication administered within 24 hours postoperatively will be recorded. Milligrams (mg) |
Within 24 hours after surgery
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Aycan KURTARANGİL DOĞAN, Kütahya City Hospital
- Hovedetterforsker: Ali Kaynak, Kütahya City Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- KSH-01
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .